Genelux (GNLX) Profit After Tax (2022 - 2026)
Genelux (GNLX) posted quarterly Profit After Tax of -$8.9 million for Q1 2026, down 18.8% year-over-year from -$11.0 million in Q1 2025, and up 3.87% quarter-over-quarter from -$9.3 million in Q4 2025.
Genelux (GNLX) Profit After Tax (2022 - 2026) Analysis & Trends
Genelux's Profit After Tax history runs 5 years deep, the most recent figure standing at -$8.9 million for Q1 2026.
- In Q1 2026, Profit After Tax fell 18.8% year-over-year to -$8.9 million; the TTM figure through Mar 2026 stood at -$33.6 million (down 14.61% YoY), while the FY2025 annual figure was -$32.2 million, down 7.98% from the prior year.
- Profit After Tax for Q1 2026 stood at -$8.9 million, up from -$9.3 million in the prior quarter.
- The five-year high for Profit After Tax was $4.9 million in Q3 2022, with the low at -$10.4 million in Q1 2023.
- The 5-year median for Profit After Tax is -$7.5 million (2025), against an average of -$6.5 million.
- The sharpest annual moves came in 2023 and 2024: Profit After Tax tumbled 208.88% in 2023, then rose 24.26% in 2024.
- Genelux's Profit After Tax stood at -$3.5 million in 2022, then slumped by 93.62% to -$6.8 million in 2023, then sank by 31.9% to -$8.9 million in 2024, then dropped by 4.21% to -$9.3 million in 2025, then rose by 3.87% to -$8.9 million in 2026.
- Business Quant data shows GNLX's Profit After Tax at -$8.9 million in Q1 2026, -$9.3 million in Q4 2025, and -$8.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -16.62 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -355.03 Mn |
| 10 | Genelux | 120.53 Mn | 120.53 Mn | - | -8.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.94 Mn |
| Dec 31, 2025 | -9.30 Mn |
| Sep 30, 2025 | -7.95 Mn |
| Jun 30, 2025 | -7.46 Mn |
| Mar 31, 2025 | -7.53 Mn |
| Dec 31, 2024 | -8.93 Mn |
| Sep 30, 2024 | -6.33 Mn |
| Jun 30, 2024 | -6.58 Mn |
| Mar 31, 2024 | -7.85 Mn |
| Dec 31, 2023 | -6.77 Mn |
| Sep 30, 2023 | -5.35 Mn |
| Jun 30, 2023 | -5.82 Mn |
| Mar 31, 2023 | -10.36 Mn |
| Dec 31, 2022 | -3.50 Mn |
| Sep 30, 2022 | 4.91 Mn |